Clinical Trial Update: Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update on BCD-100 as second-line monotherapy for non-small cell lung cancer, detailing efficacy, safety, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BCD-100 (unclear)

Snippet

Sponsor: Biocad | Conditions: Non Small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Phase 2, Phase 3 | Status: UNKNOWN